Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q3765251> ?p ?o }
Showing triples 1 to 46 of
46
with 100 triples per page.
- Q3765251 subject Q6814466.
- Q3765251 subject Q7029794.
- Q3765251 subject Q7108202.
- Q3765251 subject Q8798543.
- Q3765251 subject Q8824860.
- Q3765251 abstract "Darunavir (brand name Prezista, formerly known as TMC114) is a protease inhibitor medication used to treat HIV infection. Darunavir is an OARAC recommended treatment option for treatment-naïve and treatment-experienced adults and adolescents. It was approved by the Food and Drug Administration (FDA) on June 23, 2006.Darunavir is a second-generation protease inhibitor (PIs), designed specifically to overcome problems with the older agents in this class, such as indinavir. Early PIs often have severe side effects and drug toxicities, require a high therapeutic dose, are costly to manufacture, and show a disturbing susceptibility to drug resistant mutations. Such mutations can develop in as little as a year of use, and effectively render the drugs useless.Darunavir was designed to form robust interactions with the protease enzyme from many strains of HIV, including strains from treatment-experienced patients with multiple resistance mutations to PIs.It is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system. Darunavir received attention at the time of its release, as it represents an treatment option for people with drug-resistant HIV. Patient advocacy groups pressured developer Tibotec not to follow the previous trend of releasing new drugs at prices higher than existing drugs in the same class. Darunavir was priced to match other common PIs already in use, such as the fixed-dose combination drug lopinavir/ritonavir. The drug costs around $9,000 for a one-year supply.".
- Q3765251 bioavailability "37.0".
- Q3765251 thumbnail Darunavir_structure.svg?width=300.
- Q3765251 wikiPageExternalLink download.cfm?articleid=352436&attachmentid=51602.
- Q3765251 wikiPageExternalLink Darunavir.htm.
- Q3765251 wikiPageExternalLink ghosh.
- Q3765251 wikiPageExternalLink www.tibotec.com.
- Q3765251 wikiPageWikiLink Q11000047.
- Q3765251 wikiPageWikiLink Q1142055.
- Q3765251 wikiPageWikiLink Q12199.
- Q3765251 wikiPageWikiLink Q14864419.
- Q3765251 wikiPageWikiLink Q15787.
- Q3765251 wikiPageWikiLink Q158289.
- Q3765251 wikiPageWikiLink Q189293.
- Q3765251 wikiPageWikiLink Q204711.
- Q3765251 wikiPageWikiLink Q212410.
- Q3765251 wikiPageWikiLink Q37155.
- Q3765251 wikiPageWikiLink Q3836750.
- Q3765251 wikiPageWikiLink Q422618.
- Q3765251 wikiPageWikiLink Q42332.
- Q3765251 wikiPageWikiLink Q425490.
- Q3765251 wikiPageWikiLink Q4959983.
- Q3765251 wikiPageWikiLink Q5014970.
- Q3765251 wikiPageWikiLink Q5456317.
- Q3765251 wikiPageWikiLink Q6814466.
- Q3765251 wikiPageWikiLink Q7029794.
- Q3765251 wikiPageWikiLink Q7072287.
- Q3765251 wikiPageWikiLink Q7108202.
- Q3765251 wikiPageWikiLink Q7251230.
- Q3765251 wikiPageWikiLink Q8798543.
- Q3765251 wikiPageWikiLink Q8824860.
- Q3765251 wikiPageWikiLink Q992172.
- Q3765251 bioavailability "37".
- Q3765251 type ChemicalSubstance.
- Q3765251 type Drug.
- Q3765251 type ChemicalObject.
- Q3765251 type Thing.
- Q3765251 type Q8386.
- Q3765251 comment "Darunavir (brand name Prezista, formerly known as TMC114) is a protease inhibitor medication used to treat HIV infection. Darunavir is an OARAC recommended treatment option for treatment-naïve and treatment-experienced adults and adolescents. It was approved by the Food and Drug Administration (FDA) on June 23, 2006.Darunavir is a second-generation protease inhibitor (PIs), designed specifically to overcome problems with the older agents in this class, such as indinavir.".
- Q3765251 label "Darunavir".
- Q3765251 depiction Darunavir_structure.svg.